2017 American Transplant Congress
Hepatitis C Genotypes Among Deceased Organ Donors in the United States.
1University of Pennsylvania, Philadelphia, PA; 2Gift of Life, Philadelphia, PA
Background: HCV is one of the leading causes of liver disease in the US. 5% of deceased organ donors are HCV+ and HCV infection is…2017 American Transplant Congress
Deceased Donors with a History of IV Drug Use and Donor Derived Hepatitis C Virus.
1OPTN Ad Hoc Disease Transmission Advisory Committee, Richmond, VA; 2UNOS, Richmond
Introduction:In 2015, the CDC reported a 172% increase in heroin-related deaths from 2010 to 2013. Deceased donors with IV drug use (IVDU) are at increased…2017 American Transplant Congress
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Indiana University Health, Indianapolis
Background: Chronic Hepatitis C Virus (HCV) infection has a negative impact on graft survival. Prior treatments were poorly tolerated and had minimal cure rates. The…2017 American Transplant Congress
HCV+ Waitlist Candidates More Likely to Die Waiting for Kidney Transplant from HCV- Donor.
1University of Alabama at Birmingham, Birmingham; 2University of Pennsylvania, Philadelphia
Background: HCV-infected ESRD patients derive a significant survival benefit from kidney transplantation (KT) over remaining on dialysis. Given the high mortality rates on dialysis and…2017 American Transplant Congress
Total Pancreatectomy and Islet Autotransplantation into the Liver of a Patient with Previous Hepatitis C Infection.
Hepatic parenchymal disease such as hepatitis has been considered a relative contraindication to islet transplantation as the islets are infused into the liver. Islet transplantation…2017 American Transplant Congress
Treating Hepatitis C+ Patients Before or After Kidney Transplantation: A Medical Decision Analysis.
Some have recommended that HCV+ kidney wait list patients delay HCV treatment with direct acting antiviral agents (DAAs) with the option of receiving an HCV+/HCV-…2017 American Transplant Congress
An Investigation of Biopsy-Proven De Novo Autoimmune Hepatitis After Hepatitis C Clearance with Direct Acting Antivirals in Liver Transplant Patients.
Department of Abdominal Transplantation, Baylor College of Medicine, Houston, TX
Direct acting antivirals (DAAs) for hepatitis C virus (HCV) have been widely prescribed to post-liver transplant patients for HCV clearance and are believed to be…2016 American Transplant Congress
Utilization and Post-Transplant Outcomes Associated with Hepatitis C+ Donor Kidneys in the Advent of Direct-Acting Antivirals.
The introduction of interferon-free direct-acting antivirals(DAAs) in December 2013 dramatically improved outcomes for individuals with Hepatitis C. The impacts of these therapies on utilization and…2016 American Transplant Congress
Outcomes of Ribavirin Free Treatment of Recurrent Genotype 1 , Hepatitis C Infection Post Liver Transplant.
Background. With the development of direct-acting antivirals, the treatment of Hepatitis C Virus (HCV) has become a rapidly changing area of medical practice. Data on…2016 American Transplant Congress
The Use of Sofosbuvir (SOF)-Containing Direct Antiviral Agents (DAA)-Based Regimens Requires Increase in Tacrolimus (Tac) Doses in Kidney Transplant (KT) Recipients with Hepatitis C Virus (HCV) Infection.
Background: The use of SOF-containing regimens based on NS5A inhibitors has not been shown interactions with Tac in liver transplant.Specific data on KT recipients are…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 28
- Next Page »